Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Rapid Responses to:
|
|
Rapid Responses published:
|
|
|||
|
Anwar Chahal, Cardiology King's College Hospital, London, SE5 9RS, S. Ahsan Raza
Send response to journal:
|
As the NHS plunges further into the red, the search for innovative cost-cutting measures increases. On a very recent ward round, we were initially intrigued to notice one of our patients with Clostridium difficile diarrhoea taking IV vancomycin orally. At first we thought the IV infusion had been left on the patients table by mishap. We duly asked the patient to stop and informed the senior nurse. To our utter bewilderment we were informed this was the desired route. We explained this was an IV preparation being taken orally ?! The ward pharmacist enlightened us with the rationale: this was cheaper than purchasing oral preparations. Our concern was patient care, and whether the paradoxical constitution and route of administration were causing harm -we checked the BNF. A 28 pack of 125 mg tablets costs £66.23, whereas vancomycin power for reconstitution as an infusion costs £8.05 for a 500 mg vial and £16.11 for a 1g vial, demonstrating a clear financial saving. Furthermore, a small note at the bottom states the infusion powder 'can be used to prepare solutions for oral administration'. Innovative cost-cutting measures? You decide. Competing interests: None declared |
|||